



NANOLOGICA

INTERIM REPORT JAN-JUN 2022

NANOLOGICA AB (PUBL)

PERIOD IN BRIEF

FINANCIAL SUMMARY

- Net sales for the quarter amounted to TSEK 210 (4,497) and for the half-year to TSEK 479 (10,119)
- The operating result for the quarter amounted to TSEK -12,397 (-8,094) and for the half-year to TSEK -27,989 (-14,862)
- Result after tax for the quarter amounted to TSEK -13,473 (-9,216) and for the half-year to TSEK -29,388 (-17,061)
- Earnings per share before and after dilution were SEK -0.48 (-0.33) for the quarter and SEK -1.04 (-0.61) for the half-year period

SIGNIFICANT EVENTS DURING THE SECOND QUARTER

- NLAB Saga®, the company's silica for preparative chromatography, is launched on the market
- Loans of MSEK 40 were taken in April and in June within the credit facility that was signed with Flerie Invest AB in January

SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

- Nanologica takes order for NLAB Saga® from one of the world's largest manufacturers of insulin for evaluation on a production scale
- The first large-scale batch of NLAB Saga® is finalized
- The management team is expanded with Katarina Alenäs, SVP Chromatography, as part of the company's venture within preparative chromatography

Key Figures (group)	2022	2021	2022	2021	2021
	Apr - Jun	Apr - Jun	Jan - Jun	Jan - Jun	Jan-Dec
Net sales (TSEK)	210	4 497	479	10 119	12 914
Operating profit/loss (TSEK) *	-12 397	-8 094	-27 989	-14 862	-40 689
Profit/Loss before income tax (TSEK)	-13 473	-9 216	-29 388	-17 061	-44 829
Cash flow from operating activities (TSEK)	-12 007	-13 652	-26 751	-17 128	-46 493
Cash and cash equivalents (TSEK)	29 357	44 795	29 357	44 795	10 987
Total equity (TSEK)	22 208	79 340	22 208	79 340	51 596
Average number of shares	28 165 826	27 918 262	28 165 826	27 824 354	27 995 090
Number of shares, end of period	28 165 826	28 165 826	28 165 826	28 165 826	28 165 826
Earnings per share (basic and diluted) (SEK)	-0,48	-0,33	-1,04	-0,61	-1,60
Equity per share (SEK) *	0,79	2,82	0,79	2,82	1,83
Equity ratio (%) *	19,5%	60%	19%	60%	52%
Average number of employees	18	20	17	19	19
Number of employees, end of period	17	20	17	20	17

*Alternative key figures that are not defined by IFRS. For definition, please see note 9.

Amounts in brackets refer to comparative figures for the corresponding period of the previous year. The quarter refers to April – June 2022. Unless otherwise stated, this interim report refers to the group.

This report in English is a translation of the original report in Swedish. In case of any discrepancies, the report in Swedish has precedence.

CEO COMMENT

ORDER FROM INSULIN MANUFACTURERS LAYS FOUNDATION FOR CHARGING FORWARD

During the quarter, we launched our product line NLAB Saga® for preparative chromatography, after finalizing large volumes of the first products at the large-scale production facility. NLAB Saga® has initially been very well received by customers, which was shown by an order from one of the world's largest insulin manufacturers in August, for evaluation of the product at production scale. If the products meet the customer's expectations, we expect deliveries of commercial volumes within a year.



Large-scale production of silica was initiated in the summer of 2019. After several delays, our goal has been that the production line would be able to deliver finished products in the second quarter of this year. Although it has taken longer than we wanted, these delays are now offset by the milestone we have achieved – we have finished products and we have taken an order for evaluation at production scale from one of the largest insulin manufacturers in the world. Manufacturing on a large scale is no small thing and I am impressed by the work put in by the production team. Now that we have proven to our customers and to ourselves that we can manufacture our high-quality silica on a large scale, we are entering a very interesting phase.

During the quarter, we presented NLAB Saga® at several trade fairs in the US and in Europe. The reception of and interest in our products has been very positive. Customers who manufacture insulin and peptides only have a few suppliers of silica for preparative chromatography to choose from, in addition to us. This, combined with the fact that our products show excellent performance and enable customers to reduce production costs, means that we receive many requests.

A direct consequence of at last having finalized product, is that we can move forward in the evaluation steps with customers where we will now be able to send products for evaluation to more customers. We intend to increase sales, marketing, and application support efforts, and we will work to secure more orders from, above all, India and the US, to be able to sign supply agreements for larger volumes to include in customers' production in the next step.

In parallel with continued production, we have begun the work of increasing efficiency in the different production steps by, among others, shortening lead times and eliminating bottlenecks. We are also reviewing several possibilities for reducing our manufacturing costs.

In light of the great interest in and demand for our products, combined with, for us, favorable market conditions in the insulin and peptide market, we assess our commercial potential within preparative chromatography to be large. We believe that our business in preparative chromatography will be able to generate considerable profit for the company within the next few years and we are now evaluating how we can best strengthen our competitiveness and take advantage of the favorable market conditions by increasing our capacity.

I am convinced that the future of Nanologica is bright, and I am proud to be the company's CEO and third largest owner.

Södertälje in August
/Andreas Bhagwani, CEO



THIS IS NANOLOGICA

Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products.

Through the two business areas, Chromatography and Drug Development, the company strives towards increasing the accessibility of innovative treatments and medicines in healthcare, for the benefit of patients around the world.

In Chromatography, the company aims to make insulin and other peptide drugs available to more patients in need, by lowering the cost of manufacturing. The goal is to establish a fast-growing, sustainable, and profitable business by providing silica-based products for the analysis and purification of substances, with a focus on diabetes products.

In Drug Development, Nanologica is developing a platform technology with a unique carrier particle for delivering drugs to the respiratory system. Drug substances are encapsulated into the pores of amorphous nanoporous silica particles, for inhalation. The resulting drug products are expected to exhibit improved bioavailability and are easily aerosolized from commercially available dry powder inhalers. Feasibility studies with inhaled molecules are ongoing. The platform is developed to be able to provide new treatment options for patients with lung diseases. The goal is to create long-term values both with own products, as well as together with pharma partners.

Nanologica has a small research and production facility at the headquarter in Södertälje, where development of new products and production of silica in small scale is conducted. Since 2019, the company has invested in large-scale production capacity at a contract manufacturer in Great Britain. The large-scale production line is GMP-certified and has successfully produced material that is identical to the material produced at the plant in Södertälje.

Nanologica's share (NICA) is listed on Nasdaq Stockholm Main Market since March 29, 2022. For further information, please visit www.nanologica.com.



NANOLOGICA

BUSINESS AREA CHROMATOGRAPHY

Production of the company's first commercial silica for preparative chromatography is finalized and the product is now undergoing quality controls for release. Nanologica's silica is manufactured at a cGMP-classified facility, which means there are several analyzes and controls in the release process. This GMP-classifying is unique within preparative chromatography and something that customers perceive as a quality stamp. When the products have been released from the quality controls, they will be delivered to customers for evaluation with the purpose of including them in the customers' manufacturing processes.

In parallel with continued silica production, work is underway to optimize the manufacturing processes and increase efficiency, to shorten lead times for future production campaigns.

The launch of NLAB Saga®, Nanologica's product line for preparative chromatography, has during the second quarter mainly been focused to the US and Europe, where Nanologica participated in several conferences and trade fairs. The launch has also taken place in India and after the end of the quarter, work with the launch has intensified in China, which is now slowly opening up post-covid. The interest in the company's products is great and work continues with customers with the goal of qualifying Nanologica as a supplier in the customers' production chains and signing agreements for the

delivery of larger volumes. After the end of the quarter, Nanologica has taken an order for NLAB Saga® from one of the world's largest insulin producers, for evaluation in production scale.

During the quarter, a successful method development project was carried out together with a customer. Nanologica's application laboratory now consists of three experienced analytical chemists who assist customers in method development and problem solving.

Net sales for the Chromatography business area amounted to TSEK 210 (390) for the quarter and to TSEK 480 (531) for the half-year. The net sales were solely comprised by analytical columns, where China, followed by Egypt, accounted for the largest part of the turnover. As the company's focus in Chromatography is primarily on preparative chromatography, sales of analytical columns are expected to remain at limited levels in the coming quarters.

Operating result for the quarter amounted to TSEK -5,815 (-4,849) and for the half-year to TSEK -12,541 (-8,137). The operating result was affected by continued low sales. Furthermore, full depreciation of assets linked to large-scale production has been made since the second quarter of 2021. Depreciation and amortization in the group linked to large-scale production amounted to TSEK 1 596 during the first quarter.

Chromatography	2022 Apr - Jun	2021 Apr - Jun	2022 Jan - Jun	2021 Jan - Jun	2021 Jan - Dec
Net sales, TSEK	210	390	480	531	1 911
Raw materials, consumables and change in inventory. TSEK	-179	-339	-1 529	-208	-4 389
Gross profit, TSEK	31	51	-1 049	323	-2 478
Operating result, TSEK	-5 815	-4 849	-12 541	-8 173	-19 417
Average number of employees	8	7	8	8	8

BUSINESS AREA DRUG DEVELOPMENT

During 2021, the strategy in Drug Development was focused to explore how nanoporous amorphous particles (NAP) could be used to deliver drugs to the lungs to treat respiratory diseases. Following this, the company is conducting an extensive in-house research program to generate the data package assessed needed to support the use of the company's unique amorphous silica particles as an excipient in creating inhaled drug products. It is anticipated that the company will identify candidates for clinical development in 2023.

During the second quarter, work has progressed regarding the technical development and manufacture of NAP for inhalation. Several preclinical activities are conducted to explore the safety and tolerability of different NAP designs. The goal is to identify a NAP design that is suitable as an excipient in inhaled drug products and to demonstrate that such particles can be made reproducibly with the required particle characteristics for delivering the therapeutic drug payload.

This work will continue to be the focus during 2022 with the purpose of de-risking the inhalation

of NAPs. To conduct the inhouse research activities, Nanologica is actively building a team of scientists.

In parallel with internal work, Nanologica continues to collaborate with various academic groups to develop understanding of how NAPs can be utilized for drug delivery. These collaborations feed into the company's internal knowledge and generates valuable data.

Net sales for the Drug Development business area amounted to TSEK 0 (3,465) for the quarter and to TSEK 0 (8,946) for the half-year. The decrease for the quarter and the half-year is attributed to the partner project with Vicore Pharma being delivered in final in the fourth quarter of 2021. Net sales for Drug Development are expected to continue to be low the coming quarters as the company is currently focusing on in-house research and development. Operating profit for the quarter amounted to TSEK -3,108 (332) and for the half-year to TSEK -6,139 (221).

Drug Development	2022 Apr - Jun	2021 Apr - Jun	2022 Jan - Jun	2021 Jan - Jun	2021 Jan - Dec
Net sales, TSEK	0	3 465	0	8 946	10 361
Raw materials, consumables and change in inventory, TSEK	-12	-852	-19	-3 327	-4 770
Gross profit, TSEK	-12	2 613	-19	5 619	5 591
Operating result, TSEK	-3 108	332	-6 139	221	-6 075
Average number of employees	5	8	5	7	7

OPERATING INCOME AND RESULT

Net revenue for the quarter amounted to TSEK 210 (4,497) and for the half-year to TSEK 479 (10,119). Net revenue is solely related to revenues from sales of analytical columns within the Chromatography business area. Included in the comparison numbers is revenue from the partner project with Vicore Pharma within Drug Development which was delivered in full during the fourth quarter 2021.

The operating result for the quarter amounted to TSEK -12,397 (-8,094) and for the half-year to TSEK -27,989 (-14,862). The operating result was mainly affected by lower net sales, but also by increased personnel costs amounting to TSEK 6,490 (5,449) for the quarter.

Net financial items for the quarter amounted to TSEK -1,076 (-1,122) and for the half-year to TSEK -1,399 (-2,199). Net financial items were positively impacted by the valuation of market-listed shares owned by the company at fair value.

The result after tax for the quarter amounted to TSEK -13,473 (-9,216) and for the half-year to TSEK -29,388 (-17,061).

Earnings per share before and after dilution for the quarter were SEK -0.48 (-0.33) and SEK -1.04 (-0.61) for the half-year.

TAX

The company pays taxes and fees in accordance with applicable legislation. As regards to tax on profit or loss, the company does currently not pay any tax due to negative earnings. As of December 31, 2021, the group had tax loss deductions amounting to TSEK 203,563 and the parent company had tax loss deduction amounting to TSEK 207,324. The tax loss deductions may be activated when the requirements for activation of the deferred tax asset are met. The tax loss deductions are not time limited.

INVESTMENTS, LIQUIDITY AND FINANCIAL POSITION

On June 30, 2022, capitalized expenses for development work amounted to TSEK 11,916, compared to TSEK 12,299 at the beginning of the year. These expenses mainly relate to costs for products within Chromatography and Drug

Development, and development costs for upscaling to large-scale production of silica. The patent portfolio amounted to TSEK 1,499 compared to TSEK 1,880 at the beginning of the year.

The book value of right-of-use assets amounted to TSEK 21,816 compared to TSEK 25,085 at the beginning of the year, mainly relating to dedicated equipment for large-scale production of silica at the contract manufacturer Sterling Pharma Solutions. The book value of tangible fixed assets amounted to TSEK 2,065 compared to TSEK 2,248 at the beginning of the year. Prepaid production costs amounted to TSEK 41,585 on the balance sheet date, compared to TSEK 39,686 at the beginning of the year. This relates to advances to Sterling Pharma Solutions for ongoing production of the first ton scale campaign of Nanologica's silica.

Total cash flow for the quarter amounted to TSEK 25,399 (-12,269) and for the half-year to TSEK 18,359 (-21,573).

Cash flow for operating activities for the quarter amounted to TSEK -12,007 (-13,652) and for the half-year to TSEK -26,751 (-17,128). Cash flow from operating activities has been negatively affected by the company being in an expansion phase with increased costs and low sales.

Cash flow from investment activities for the quarter amounted to TSEK -1,233 (-866) and for the half-year to TSEK -2,175 (5,464). The investments during the quarter are mainly related to intangible assets in the form activated work for own account connected to the company's inhalation platform, as well as patents and patent applications.

Cash flow from financial activities amounted to TSEK 38,640 (2,249) and for the half-year to TSEK 47,286 (1,019). During the quarter, loans of MSEK 40 were taken within the credit facility of up to MSEK 50 that was agreed with Flerie Invest AB in January 2022. The credit facility has thus been used in full.

As per June 30, 2022, cash and cash equivalents amounted to TSEK 29,357 (44,795). Total equity amounted to TSEK 22,208 compared to TSEK 51,596 at the beginning of the year. The equity/assets ratio was 19 percent as per June 30, compared to 52 percent at the beginning of the year.

FLUCTUATIONS IN REVENUE GENERATION

Nanologica has two business areas that generate revenue.

Chromatography generates revenue through the sales of products for analytical and preparative chromatography. Sales of products for preparative chromatography are from the second half of 2022 expected to constitute the majority of the net sales for the company. The sales of products for analytical chromatography will then be of a supportive nature and not the main business.

Drug Development has previously generated revenues from partner collaborations and licensing agreements. Revenues fluctuate depending on the nature, phase, and structure of the projects, which means that larger projects and agreements can have significant effects on revenue and result for individual quarters. Revenue and result developments should therefore be assessed over a longer period of time.

Nanologica lacks significant seasonal variations.

EMPLOYEES AND ORGANIZATION

As per June 30, 2022, the number of permanent employees was 17 (20), whereof 8 in Chromatography, 4 in Drug Development and 5 in Business Support. 11 (13) were women and 6 (7) were men. 4 persons work in R&D and out of the total number of employees, 6 are PhDs. To conduct an efficient business with a cost-effective organization, Nanologica hires consultants, advisors and project employees for specific assignments and tasks in areas of competence that the company lacks or only periodically needs. As per June 30, 2022, the number of consultants and project employees corresponds to 1, (3) full-time equivalent in Chromatography.

PATENTS

At the end of the quarter, Nanologica's patent portfolio consisted of three patent families with more than 30 granted patents and over 10 pending patent applications. In accordance with the company's IP policy, during the second quarter three patent families were abandoned as they are no longer considered to have commercial value for the company.

PARTNERSHIPS, COLLABORATIONS AND ESSENTIAL AGREEMENTS

No new partnerships, collaborations or essential agreements have been entered into during the first quarter. Further information is available in Nanologica's Annual Report 2021.

FUTURE PROSPECTS

This report contains forward-looking statements. Actual outcomes may differ from these statements. Internal and external factors can affect Nanologica's results.

When large-scale production of silica has been established, sales in preparative chromatography are expected to increase and make up the majority of Nanologica's revenue. The company considers it reasonable to achieve sales in preparative chromatography of MSEK 100-300 in 2024, based on the customer dialogues that are currently carried out.

Nanologica's projects in the Drug Development business area are expected to focus primarily on inhaled drugs and respiratory diseases. The company intends to run its own projects as well as projects with partners. Proving the technology in your own projects is expected to increase the possibility of economically advantaged partner projects. Positive cash flow from the Chromatography business area can facilitate the financing of the company's Drug Development business area, which requires significant investments before it is expected to generate greater revenue.

In 2022, the company's sales within Chromatography are expected to increase significantly, mainly due to sales of products for preparative chromatography. Costs are also expected to increase, both as a result of higher production costs in the Chromatography business area and costs for the inhalation program in the Drug Development business area.

RISKS AND UNCERTAINTIES

The company makes assumptions, assessments and estimates that affect the content of the financial statements. Actual outcomes may differ from these assessments and estimates, as stated in the accounting principles. The goal of the group's risk management is to identify, prevent,

measure, control and limit the risks in the business. Significant risks are the same for the parent company and the group.

The risks in Nanologica's operations include strategic risks related to, among other things, the company's operations, industry, legal and regulatory risks, such as financing of upscaling projects, commercialization, dependence on partners, research, trademarks, patents and external requirements, and operational risks such as production risks, price changes on raw materials and inputs, and currency fluctuations. A detailed description of risk exposure and risk management can be found in Nanologica's Annual Report for 2021 on pages 56–60.

IMPACT OF COVID-19

As a result of the pandemic, delivery of a larger amount of product from large-scale production of silica has been delayed. In particular, it is the supply of equipment, raw materials and spare parts for new machines and rebuilding of machines and premises that has taken longer than expected and thus delayed the project. No further delays due to the pandemic are expected in the second quarter, but this cannot be ruled out.

Travel restrictions in China during the quarter have made it more difficult to travel to and within China. The company has therefore refrained from travels to China. This has partly affected the launch of NLAB Saga®, which to begin with has been done partly digitally, partly together with the company's local partner Yunbo.

THE WAR IN UKRAINE

During the second quarter, the war in Ukraine and the subsequent sanctions against Russia had no direct impact on the company or its employees. There is however a continued uncertainty on both the commodity market and the financial market. A protracted war may affect the supply and price of raw materials and components, as well as logistics. At the time of publication of the report, Nanologica does not conduct any business activities linked to either Ukraine or Russia.

THE SHARE AND SHAREHOLDERS

Nanologica's share is listed on Nasdaq Stockholm Main Market since March 29, 2022. The ticker is

NICA and the ISIN code is SE0005454873. There is one class of shares, and all shares have equal voting rights as well as share of the company's assets and earnings. The company's share register is kept electronically by Euroclear Sweden AB. The number of outstanding shares at the end of the first quarter amounted to 28,165,826 and the market capitalization was approximately MSEK 335. The share capital amounted to SEK 11,548,771 SEK and the share quota was SEK 0.41.

Owners as of June 30, 2022	Shares	Share %
Flerie Invest AB	8 982 639	31,9
Swedbank Robur Microcap	2 499 675	8,9
Vega Bianca AB	2 014 764	7,2
Konstakademien	1 299 000	4,6
Avanza Pension	1 209 531	4,3
Niklas Sjöblom	564 594	2,0
Rahal Investment AB	481 178	1,7
SEB Life International	425 085	1,5
Nordic Cross Asset Management	382 421	1,4
Andre Oscar o Anna Wallenbergs stiftelse	373 000	1,3
The ten largest shareholders	18 231 887	65,4
Other shareholders (2 252)	9 933 939	34,6
Total	28 165 826	100,0

SHARE-BASED INCENTIVE PROGRAMS

At the end of the second quarter, there were three active stock option programs.

In the stock option program 2020/22 for the board of directors, all 350,000 options were subscribed and allocated. In the stock option program 2020/22 for the management and employees, 569,949 of the total 698,577 options were subscribed and allocated. Each option entitles the holder to subscribe for one share in the company at a subscription price corresponding to SEK 18, during the period 1 July 2020 to 1 July 2022. Based on the existing number of shares, the dilution will be a maximum of approximately 3.2 percent if all options are exercised.

After the end of the second quarter, the two programs described above have expired. No options were exercised in either of the programs.

In the option program 2021/2024 for the management team and employees, all of the 800,000 options were subscribed for. Each option entitles the holder to subscribe for one share in

the company at a subscription price corresponding to SEK 45, during the period 1 July 2021 to 1 July 2024. Based on the existing number of shares, the dilution will be a maximum of approximately 2.8 percent if all options are exercised.

ACCOUNTING AND VALUATION PRINCIPLES

The group's accounting principles are based on IFRS. The group's interim report has been prepared in accordance with IAS 34 Interim Reporting and the Swedish Annual Accounts Act. The same accounting and valuation principles as in the most recent annual report have been applied. More information regarding accounting and valuation principles can be found on pages 72–80 in Nanologica's annual report 2021.

Amounts are expressed in TSEK and MSEK, which in this interim report refers to thousands of Swedish kronor and millions of Swedish kronor. Amounts in brackets refer to comparative figures for the previous year. Information for the quarter refers to the second quarter of 2022 unless otherwise stated.

RELATED PARTY TRANSACTIONS

Second quarter

Loans of MSEK 40 (MSEK 20 in April and MSEK 20 in June) were taken within the credit facility of up to MSEK 50 that was agreed with Flerie Invest AB in January. The credit facility has thus been used in full.

Costs during the quarter regarding loans from Flerie Invest AB amounted to TSEK 917 and relate to interest and commitment fee. Interest payments are made quarterly in advance.

Loans from Flerie Invest AB were raised on market terms and amounted to MSEK 67 as of June 30, 2022. Loan 1 totaling MSEK 17 was raised during autumn 2019 and spring 2020. The interest rate is 8 percent, and the loan is due for payment in July 2023. Loan 2 totaling MSEK 50 was raised during the first half of 2022. The interest rate is 8 percent, and the loan is due for payment in July 2025.

Flerie Invest AB is owned by Thomas Eldered, who is a board member of Nanologica as well as the company's largest owner through Flerie Invest AB. More information on transactions with related parties can be found in Nanologica's annual report 2021, note 37.

FINANCIAL CALENDAR

Interim report Jan-Sep 2022	Oct 28, 2022
Year-end report Jan-Dec 2022	Feb 10, 2023
Annual report 2022	March 24, 2023

Important events and financial reports are published through press releases and on the company's website www.nanologica.com, where they are also kept available. Through a subscription service on the company's website, it is possible to subscribe to Nanologica's reports and press releases via e-mail.

AUDITORS REVIEW

This interim report has not been subject to review by the company's auditors.

ASSURANCE

The board of directors and the CEO provide their assurance that the interim report provides a fair and true overview of the parent company's and the group's operations, financial position, and results, and describes material risks and uncertainties faced by the parent company and the companies in the group.

August 18, 2022

Gisela Sitbon
Chairman

Mattias Bengtsson
Board member

Eva Byröd
Board member

Thomas Eldered
Board member

Tomas Kramar
Board member

Anders Rabbe
Board member

Lena Torlegård
Board member

Andreas Bhagwani
Chief Executive Officer



FINANCIAL REPORTS AND NOTES

CONSOLIDATED INCOME STATEMENT

Amounts in TSEK	2022 Apr - Jun	2021 Apr - Jun	2022 Jan - Jun	2021 Jan - Jun	2021 Jan - Dec
Net sales	210	4 497	479	10 119	12 914
Change in inventory, finished goods	21	21	-1 202	744	-2 301
Capitalized work for own account	1 113	366	1 518	944	1 809
Other operating income	55	302	134	360	1 088
Operating expenses					
Raw materials and consumables	-212	-1 856	-347	-4 923	-7 502
Other external expenses	-3 654	-2 890	-8 671	-6 271	-12 583
Personnel costs	-6 490	-5 449	-13 285	-10 535	-21 222
Depreciation, amortization and impairment of plant, property, and equipment	-2 910	-2 916	-5 797	-4 679	-10 463
Other operating expenses	-530	-169	-819	-623	-2 430
Total operating expenses	-13 796	-13 280	-28 918	-27 030	-54 199
Operating profit/loss	-12 397	-8 094	-27 989	-14 862	-40 689
Financial items					
Valuation of financial assets at fair value	192	-300	640	-556	-902
Financial income	-12	-9	11	-1	3
Financial costs	-1 257	-813	-2 050	-1 641	-3 242
Total financial items	-1 076	-1 122	-1 399	-2 199	-4 140
Profit/loss before income tax	-13 473	-9 216	-29 388	-17 061	-44 829
Income tax	0	0	0	0	0
Profit/loss for the period attributable to owners of parent company	-13 473	-9 216	-29 388	-17 061	-44 829
Other comprehensive income	0	0	0	0	0
Total comprehensive profit/loss for the period attributable to owners of parent company	-13 473	-9 216	-29 388	-17 061	-44 829
Earnings per share (basic and diluted), SEK	-0,48	-0,33	-1,04	-0,61	-1,60
Average number of ordinary shares during the period	28 165 826	27 918 262	28 165 826	27 824 354	27 995 090
Ordinary shares outstanding at the closing date	28 165 826	28 165 826	28 165 826	28 165 826	28 165 826

CONSOLIDATED BALANCE SHEET

Amounts in TSEK	2022 Jun 30	2021 Jun 30	2021 Dec 31
ASSETS			
Noncurrent assets			
Intangible assets			
Capitalized expenses for development work and similar work	11 916	14 365	12 299
Concessions, patents, licenses, trademarks and similar rights	1 499	1 826	1 880
Total intangible assets	13 415	16 191	14 179
Tangible fixed assets			
Equipment, tools and installations	2 065	2 106	2 248
Right-of-use assets			
Right-of-use assets	21 816	28 353	25 085
Total noncurrent assets	37 296	46 651	41 512
Current assets			
Inventories			
Inventories	1 245	5 334	2 408
Current receivables			
Accounts receivable	378	2 630	1 421
Other receivables	289	535	493
Prepaid expenses and accrued income	44 133	30 268	40 780
Total current receivables	44 800	33 433	42 694
Financial assets (current)			
Financial assets at fair value through profit or loss	1 354	1 059	714
Cash and cash equivalents			
Cash and cash equivalents	29 357	44 795	10 987
Total current assets	76 756	84 620	56 803
TOTAL ASSETS	114 052	131 271	98 316

CONSOLIDATED BALANCE SHEET

Amounts in TSEK	2022 Jun 30	2021 Jun 30	2021 Dec 31
EQUITY AND LIABILITIES			
Equity			
Share capital including ongoing issues	11 549	11 549	11 549
Additional paid-in capital	234 674	234 650	234 674
Retained earnings incl. profit/loss from actual period	-224 015	-166 858	-194 627
Total equity	22 208	79 340	51 596
Total equity attributable to parent company shareholders	22 208	79 340	51 596
Noncurrent liabilities			
Liabilities to credit institutions	333	2 333	1 333
Lease liabilities	1 926	4 744	3 359
Provisions	551	522	530
Other noncurrent liabilities	66 523	27 000	27 000
Total noncurrent liabilities	69 332	34 600	32 222
Current liabilities			
Liabilities to credit institutions	2 000	2 720	2 360
Advanced payment from customers	692	2 204	946
Accounts payable	1 773	4 468	3 685
Lease liabilities	2 819	2 662	2 739
Other liabilities	1 573	1 191	1 443
Accrued expenses and deferred income	3 655	4 087	3 325
Total current liabilities	22 511	17 331	14 498
Total liabilities	91 844	51 930	46 719
TOTAL EQUITY AND LIABILITIES	114 052	131 271	98 316

CONSOLIDATED REPORT OF CHANGES IN EQUITY

Amounts in TSEK	2022 Apr - Jun	2021 Apr - Jun	2022 Jan - Jun	2021 Jan - Jun	2021 Jan - Dec
Total equity at the beginning of the period	35 681	85 103	51 596	92 966	92 966
Rights issue	0	3 453	0	3 453	3 453
Premiums for issued / repurchased warrants	0	0	0	-18	6
Total comprehensive income for the period	-13 473	-9 216	-29 388	-17 061	-44 829
Total equity at the end of the period	22 208	79 340	22 208	79 340	51 596

CONSOLIDATED CASH FLOW ANALYSIS

Amounts in TSEK	2022 Apr - Jun	2021 Apr - Jun	2022 Jan - Jun	2021 Jan - Jun	2021 Jan - Dec
Operating activities					
Operating profit/loss	-12 397	-8 094	-27 989	-14 862	-40 688
Adjustment for items not affecting cash flow	3 340	2 916	6 285	4 679	11 630
Interest paid	-1 929	-727	-3 217	-4 162	-5 565
Income taxes received/paid	0	0	0	0	0
Cash flow from operating activities before changes in working capital	-10 985	-5 905	-24 920	-14 345	-34 623
<i>Cash flow from changes in working capital</i>					
Increase (-) / decrease (+) of inventories	-7	-21	1 163	-744	2 182
Increase (-) / decrease (+) of operating receivables	521	-5 635	-1 398	-2 841	-12 237
Increase (+) / decrease (-) of operating liabilities	-1 535	-2 091	-1 595	803	-1 814
Cash flow from operating activities	-12 007	-13 652	-26 751	-17 128	-46 493
Investing activities					
Acquisitions in intangible assets	-1 305	-373	-1 960	-3 701	-5 122
Acquisitions in tangible fixed assets	0	-415	-287	-444	-808
Acquisitions in right-of-use assets	0	-78	0	-1 319	-1 319
Compensation sold tangible fixed assets	72	0	72	0	0
Cash flow from investing activities	-1 233	-866	-2 175	-5 464	-7 249
Financing activities					
Rights issue for the year	0	3 454	0	3 454	3 454
Premiums for issued/reissued warrants	0	0	0	-19	-19
New borrowings	40 000	0	50 000	0	0
Amortization of lease liabilities	-680	-525	-1 354	-1 045	-2 343
Amortization of financial loans	-680	-680	-1 360	-1 370	-2 730
Cash flow from financing activities	38 640	2 249	47 286	1 019	-1 639
Total cash flow for actual period	25 399	-12 269	18 359	-21 573	-55 381
Cash and cash equivalents, opening balance	3 969	57 069	10 987	66 364	66 364
Exchange rate difference in cash and cash equivalents	-12	-5	10	4	4
Cash and cash equivalents, closing balance	29 357	44 795	29 357	44 795	10 987

INCOME STATEMENT FOR THE PARENT COMPANY

Amounts in TSEK	2022 Apr - Jun	2021 Apr - Jun	2022 Jan - Jun	2021 Jan - Jun	2021 Jan - Dec
Net sales	210	4 497	479	10 119	12 914
Change in inventory, finished goods	21	21	-1 202	744	-2 301
Capitalized work for own account	1 113	366	1 518	944	1 809
Other operating income	55	302	134	360	1 088
Operating expenses					
Raw materials and consumables	-212	-1 856	-347	-4 923	-7 502
Other external expenses	-4 405	-3 539	-10 173	-7 479	-15 187
Personnel costs	-6 490	-5 449	-13 285	-10 535	-21 222
Depreciation, amortization and impairment of plant, property, and equipment	-2 319	-2 367	-4 615	-4 643	-9 245
Other operating expenses	-530	-169	-819	-623	-2 430
Total operating expenses	-13 956	-13 380	-29 238	-28 203	-55 586
Operating profit/loss	-12 556	-8 193	-28 309	-16 035	-42 075
Financial items					
Profit/loss from group companies	-28	-76	-55	-154	-282
Result/loss from other financial items	192	-300	640	-556	-902
Currency effects	0	0	0	0	0
Interest income and similar income	-12	-9	11	-1	3
Interest expense and similar expenses	-1 205	-741	-1 939	-1 505	-2 969
Profit/loss from financial items	-1 052	-1 126	-1 344	-2 217	-4 150
Profit/loss before income tax	-13 609	-9 319	-29 652	-18 252	-46 225
Income tax	0	0	0	0	0
Profit/loss for the period	-13 609	-9 319	-29 652	-18 252	-46 225

STATEMENT OF COMPREHENSIVE INCOME FOR PARENT COMPANY

Amounts in TSEK	2022 Apr - Jun	2021 Apr - Jun	2022 Jan - Jun	2021 Jan - Jun	2021 Jan - Dec
Profit/loss for the period	-13 609	-9 319	-29 652	-18 252	-46 225
Other comprehensive income					
Items that may be reclassified to result for the year	0	0	0	0	0
Comprehensive income for the period	-13 609	-9 319	-29 652	-18 252	-46 225

BALANCE SHEET FOR THE PARENT COMPANY

Amounts in TSEK	2022 30 Jun	2021 30 Jun	2021 Dec 31
ASSETS			
Noncurrent assets			
Intangible assets			
Capitalized expenses for development work and similar work	23 757	30 380	26 228
Concessions, patents, licenses, trademarks and similar rights	1 499	1 826	1 880
Total intangible assets	25 256	32 207	28 108
Tangible fixed assets			
Equipment, tools and installations	2 065	2 106	2 248
Financial non-current assets			
Participations in group companies	100	100	100
Total noncurrent assets	27 422	34 412	30 456
Current assets			
Inventories			
Inventories	1 245	5 334	2 408
Current receivables			
Accounts receivable	378	2 630	1 421
Receivables from group companies	0	61	24
Other receivables	286	531	464
Prepaid expenses and accrued income	45 352	31 660	42 087
Total current receivables	46 016	34 881	43 996
Financial assets (current)			
Financial assets at fair value through profit or loss	1 354	1 059	714
Cash and cash equivalents			
Cash and cash equivalents	29 198	44 598	10 839
Total current assets	77 813	85 872	57 957
TOTAL ASSETS	105 235	120 285	88 413

BALANCE SHEET FOR THE PARENT COMPANY

Amounts in TSEK	2022 30 Jun	2021 30 Jun	2021 Dec 31
EQUITY AND LIABILITIES			
Equity			
Share capital	11 549	11 397	11 549
Fund for development expenditure	5 062	5 395	4 386
Total restricted equity	16 611	16 944	15 935
Non-restricted equity			
Share premium reserve	234 674	234 650	234 674
Retained earnings	-203 450	-157 559	-156 549
Result for the period	-29 652	-18 252	-46 225
Total non-restricted equity	1 571	58 839	31 900
Total equity	18 182	75 783	47 834
Provisions			
Other provisions	551	522	530
Noncurrent liabilities			
Liabilities to credit institutions	333	2 333	1 333
Other noncurrent liabilities	66 523	27 000	27 000
Total noncurrent liabilities	66 856	29 333	28 333
Current liabilities			
Liabilities to credit institutions	2 000	2 720	2 360
Advanced payment from customers	692	2 204	946
Accounts payable	1 773	4 468	3 685
Other liabilities	1 535	1 191	1 408
Accrued expenses and deferred income	3 646	4 065	3 317
Total current liabilities	19 646	14 646	11 716
Total liabilities	87 053	44 502	40 579
TOTAL EQUITY AND LIABILITIES	105 235	120 285	88 413

REPORT OF CHANGES IN EQUITY FOR THE PARENT COMPANY

Amounts in TSEK	2022 Apr - Jun	2021 Apr - Jun	2022 Jan - Jun	2021 Jan - Jun	2021 Jan - Dec
Total equity at the beginning of the period	31 790	81 649	47 834	90 601	90 601
Rights issue	0	3 453	0	3 453	3 453
Premiums for issued / repurchased warrants	0	0	0	-19	5
Total comprehensive income for the period	-13 609	-9 319	-29 652	-18 252	-46 225
Total equity at the end of the period	18 181	75 783	18 181	75 783	47 834

CASH FLOW ANALYSIS FOR THE PARENT COMPANY

Amounts in TSEK	2022 Apr - Jun	2021 Apr - Jun	2022 Jan - Jun	2021 Jan - Jun	2021 Jan - Dec
Operating activities					
Operating profit/loss	-12 556	-8 193	-28 308	-16 035	-42 075
Adjustment for items not affecting cash flow	2 749	2 367	5 103	4 643	10 412
Interest paid	-1 877	-656	-3 106	-4 027	-5 286
Income taxes received/paid	0	0	0	0	0
Cash flow from operating activities before changes in working capital	-11 684	-6 482	-26 311	-15 419	-36 949
<i>Cash flow from changes in working capital</i>					
Increase (-) / decrease (+) of inventories	-7	-21	1 163	-744	2 182
Increase (-) / decrease (+) of operating receivables	564	-5 593	-1 310	-4 004	-13 289
Increase (+) / decrease (-) of operating liabilities	-1 542	-2 092	-1 603	803	-1 795
Cash flow from operating activities	-12 669	-14 188	-28 061	-19 364	-49 851
Investing activities					
Acquisitions in intangible assets	-1 305	-373	-1 960	-3 701	-5 122
Acquisitions in tangible assets	0	-415	-287	-444	-808
Acquisitions in group companies	-28	-75	-55	-153	-281
Compensation for sold tangible assets	72	0	72	0	0
Compensation for divested financial assets	0	0	0	0	0
Cash flow from investing activities	-1 261	-863	-2 230	-4 298	-6 211
Financing activities					
Rights issue for the year	0	3 454	0	3 454	3 454
Premiums for issued/reissued warrants	0	0	0	-19	-19
New borrowings	40 000	0	50 000	0	0
Amortization of financial loans	-680	-680	-1 360	-1 360	-2 720
Cash flow from financing activities	39 320	2 774	48 640	2 075	715
Total cash flow for actual period	25 390	-12 277	18 349	-21 587	-55 347
Cash and cash equivalents, opening balance	3 820	56 879	10 839	66 183	66 183
Exchange rate difference in cash and cash equivalents	-12	-4	10	2	3
Cash and cash equivalents, closing balance	29 198	44 598	29 198	44 598	10 839

NOTES

NOTE 1 GENERAL INFORMATION

This report covers the Swedish parent company Nanologica AB (publ), corporate registration number 556664-5023, and its subsidiaries. The parent company is a limited liability company with its registered office in Stockholm, Sweden. The address of the main office is Forskargatan 20 G, 151 36 Södertälje, Sweden. The main operation of the group is sales of silica-based chromatography products, and research and development of pharmaceutical products. Nanologica AB has five subsidiaries: Nanghavi AB, Nanologica Australia Ltd, Nanologica Black AB, Nanologica Yellow AB and Nlab Bioscience S.A. Nanologica Australia Ltd has limited activities linked to research and Nlab Bioscience S.A is under liquidation. The other companies are dormant at the time of the publication of the report.

The interim report for the second quarter 2022 has been approved for publication on August 19, 2022, in accordance with a board decision on August 18, 2022.

NOTE 2 ACCOUNTING PRINCIPLES

The consolidated financial statements for Nanologica AB (publ) have been prepared in accordance with IFRS (International Financial Reporting Standards) as adopted by the EU, the Annual Accounts Act and the Swedish Financial Reporting Board's RFR 1 Supplementary Accounting Rules for Groups. The parent company's financial statements are presented in accordance with the Swedish Annual Accounts Act and RFR 2 Accounting for Legal Entities.

This interim report is presented in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. Disclosures in accordance with IAS 34 are presented both in notes and elsewhere in interim report. The accounting principles and calculation methods applied are in accordance with those described in the Annual Report 2020. The guidelines of the European Securities and Markets Authority (ESMA) on alternative performance measures have been applied. This involves disclosure requirements for financial measures that are not defined by IFRS. For performance measures not defined by IFRS, see the Definition of key figures section.

NOTE 3 IMPORTANT SOURCES OF UNCERTAINTIES IN ESTIMATES

Important estimates and assessments are described in detail in the Annual Report 2021 on pages 80–81. No significant changes in estimates and assessments have been noted for the reporting period. This report contains assumptions, assessments and estimates that affect the content of the financial statements. Actual outcomes may differ from these assessments and estimates.

NOTE 4 SEGMENTS

An operating segment is part of a group that conducts operations from which it can generate revenue and incur costs, and for which independent financial information is available. The group's division into operating segments is consistent with the internal reports that the group's highest executive decision-makers use to monitor operations and allocate resources among operating segments. The CEO is the group's highest executive decision-maker. In Nanologica, it is therefore the reports that the CEO receives on earnings in different parts of the group that form the basis for the segment information. Two operating segments have been identified in the group: Drug Development and Chromatography. Under the headline Business support, support functions that are not directly attributable to commercial segments is reported (e.g., the company's management, communication/marketing, finance, etc.). Segment information is provided only for the group. In the table below, the business area Chromatography is titled *Chroma*, and the business area Drug Development is titled *DD*.

Amounts in TSEK	2022 Apr - Jun			
	Chroma	DD	Corp Function	Total
Net sales	210	0	0	210
Raw materials, consumables and change in inventory	-179	-12	0	-191
Gross profit	31	-12	0	19
Other operating items	-5 846	-3 096	-3 474	-12 416
Operating profit/loss	-5 815	-3 108	-3 474	-12 397
Net finance			-1 076	-1 076
Profit/loss after financial items	-5 815	-3 108	-4 550	-13 473

Amounts in TSEK	2021 Apr - Jun			
	Chroma	DD	Corp Function	Total
Net sales	390	3 465	642	4 497
Raw materials, consumables and change in inventory	-339	-852	-644	-1 835
Gross profit	51	2 613	-2	2 662
Other operating items	-4 900	-2 281	-3 575	-10 756
Operating profit/loss	-4 849	332	-3 577	-8 094
Net finance			-1 122	-1 122
Profit/loss after financial items	-4 849	332	-4 699	-9 216

Amounts in TSEK	2022 Jan - Jun			
	Chroma	DD	Corp Function	Total
Net sales	480	0	0	480
Raw materials, consumables and change in inventory	-1 529	-19	0	-1 548
Gross profit	-1 049	-19	0	-1 068
Other operating items	-11 492	-6 122	-9 307	-26 921
Operating profit/loss	-12 541	-6 141	-9 307	-27 989
Net finance	0	0	-1 399	-1 399
Profit/loss after financial items	-12 541	-6 141	-10 706	-29 388

Amounts in TSEK	2021 Jan - Jun			
	Chroma	DD	Corp Function	Total
Net sales	531	8 946	642	10 119
Raw materials, consumables and change in inventory	-208	-3 327	-644	-4 178
Gross profit	323	5 619	-2	5 941
Other operating items	-8 496	-5 399	-6 908	-20 803
Operating profit/loss	-8 173	220	-6 910	-14 862
Net finance	0	0	-2 199	-2 199
Profit/loss after financial items	-8 173	220	-9 109	-17 061

NOTE 5 DISTRIBUTION OF INCOME

Nanologica's distribution of revenues for sales of goods and provision of services at a specific time and over time divided per geographic market and reported separately for major customers.

Composition of net sales, per segment and region (TSEK)	2022	2021	2022	2021	2021
	Apr - Jun	Apr - Jun	Jan - Jun	Jan - Jun	Jan - Dec
Chromatography	210	390	480	531	1 911
<i>China</i>	152	332	339	345	1 309
<i>USA</i>	0	0	0	0	103
<i>Rest of the World</i>	58	58	141	186	499
Drug development	0	3 465	0	8 946	10 361
<i>Sweden</i>	0	2 949	0	7 828	9 243
<i>Rest of the World</i>	0	516	0	1 118	1 118
Business development	0	642	0	642	642
<i>Rest of the World</i>	0	642	0	642	642
	210	4 497	480	10 119	12 914

Composition of net sales, large customers (TSEK)	2022	2021	2022	2021	2021
	Apr - Jun	Apr - Jun	Jan - Jun	Jan - Jun	Jan - Dec
Customer A - Drug Development	0	2 949	0	7 829	9 244
Customer A (%)	0%	66%	0%	77%	72%
Customer B - Drug Development	0	516	0	1 118	1 118
Customer B (%)	0%	11%	0%	11%	9%
Customer C - Chromatography	152	332	339	345	1 309
Customer C (%)	72%	7%	71%	3%	10%
Others	58	700	141	827	1 243
Others (%)	28%	16%	29%	8%	10%
	210	4 497	480	10 119	12 914

NOTE 6 FINANCIAL ASSETS VALUED AT FAIR VALUE

Fair value valuation

IFRS 13 Fair value valuation contains a valuation hierarchy regarding input to the valuations. This valuation hierarchy is divided into three levels, consisting of:

- Level 1 - Quoted prices on active markets for identical assets and liabilities
- Level 2 - Observable inputs for the asset or liability other than quoted prices including in level 1, either directly or indirectly (i.e. derived from quotations).
- Level 3 - Input of the asset or liability that is not based on observable market data (i.e. non-observable inputs).

Short-term financial investments

Holdings in short-term financial investments are continuously measured at fair value with a change in value in profit or loss. Holdings in listed shares are continuously valued at fair value according to Level 1 of the valuation hierarchy. Listed holdings are valued on the basis of the share price at the balance sheet date.

Valuation of financial assets at fair value (TSEK)	2022	2021	2022	2020	2021
	Apr - Jun	Apr - Jun	Jan - Jun	Jan - Jun	Jan - Dec
Vicare Pharma Holding AB (publ), Nasdaq Stockholm Small Cap	192	-300	640	113	-902

Financial assets valued at fair value via the income statement (TSEK)	2022 Jun 30	2021 Jun 30	2021 Dec 31
Vicore Pharma Holding AB (publ), Nasdaq Stockholm Small Cap			
- number of shares	51 285	51 285	51 285
- market value, Nasdaq Stockholm Small Cap (SEK)	26,40	20,65	13,92
Book value	1 354	1 059	714

NOTE 7 INVENTORIES

Amounts in TSEK	2022 Jun 30	2021 Jun 30	2021 Dec 31
Raw materials	48	60	53
Semi-finished products and production in progress	1 059	4747	2188
Finished products	138	527	167
Sum	1 245	5 334	2 408

NOTE 8 SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

- Nanologica takes order for NLAB Saga® from one of the world's largest manufacturers of insulin for evaluation on a production scale
- The first large-scale batch of NLAB Saga® is finalized
- The management team is expanded with Katarina Alenäs, SVP Chromatography, as part of the company's venture within preparative chromatography

NOTE 9 DEFINITION OF KEY FIGURES

In this report, the company recognizes certain financial ratios that are not defined by IFRS. Alternative key ratios should not be seen as substitutes for financial information presented in accordance with IFRS, but as a complement.

Key figure	Definition	Motivation for use
Average number of shares during the period	Calculated as an average of the number of ordinary shares outstanding during the reporting period on a daily basis after redemption and repurchase.	In order to obtain an average value over time in the event of a change in the number of shares during the period
Equity per share, SEK	Total equity divided by the number of outstanding shares at the end of the period.	Key figures used to highlight the owners' share of the company's net assets per share.
Equity ratio, %	Equity divided by the balance sheet total.	Key figures showing the proportion of assets financed with equity. The aim is to be able to assess the group's ability to pay in the long term.
Equity	The group's reported equity at the balance sheet date.	Financial key ratio to assess the financial situation.
Number of shares	The number of ordinary shares outstanding is calculated at the balance sheet date.	Key figures to show shareholders the total number of shares and put in relation to other figures in the income statement and balance sheet.
Operating profit/loss	Operating profit/loss before financial items and tax.	Financial key ratios that the company regards as relevant to understand the generation of earnings in the business.
Operating profit/loss before tax	Profit/loss before tax.	Financial key ratio that the company considers relevant to understand the results of the entire business.

Derivation

Derivation	2022 30 Jun	2021 30 Jun	2021 Dec 31
A. Equity according to the balance sheet (TSEK)	22 208	79 340	51 596
B. Total assets according to balance sheet (TSEK)	114 052	131 271	98 316
"A/B" = Equity ratio (%)	19%	60%	52%
A. Equity according to the balance sheet (TSEK)	22 208	79 340	51 596
B. Number of shares before and after dilution*	28 165 826	28 165 826	28 165 826
"A/B"1000 = Equity per share (SEK)*	0,79	2,82	1,83

GROUP QUARTERLY DATA

Amounts in TSEK unless otherwise stated	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3
Statement of comprehensive income								
Net sales	210	270	676	2 119	4 497	5 622	6 071	2 089
Total operating expenses	-13 796	-15 122	-13 406	-13 763	-13 280	-13 750	-9 958	-8 659
Operating profit/loss (EBIT) *	-12 397	-15 592	-14 108	-11 718	-8 094	-6 768	-3 648	-5 795
Operating margin,%	neg	neg	neg	neg	neg	neg	neg	neg
Total financial investments	-1 076	-323	-1 114	-827	-1 122	-1 077	-1 779	-104
Profit/loss before income tax	-13 473	-15 915	-15 222	-12 546	-9 216	-7 845	-5 427	-5 899
Consolidated financial position								
Total noncurrent assets	37 296	39 403	41 512	43 270	46 651	46 864	45 180	43 826
Total current assets	76 756	50 985	56 803	72 282	84 620	91 681	101 165	105 720
Cash and cash equivalents	29 357	3 969	10 987	28 624	44 795	57 069	66 364	82 203
Total equity	22 208	35 681	51 596	66 794	79 340	85 103	92 966	98 604
Total noncurrent liabilities	69 332	40 515	32 222	33 416	34 600	34 422	35 645	36 875
Total current liabilities	22 511	14 193	14 498	15 341	17 331	19 021	17 735	14 067
Consolidated statement of cash flow								
Cash flow from operating activities	-12 007	-14 744	-15 213	-14 152	-13 652	-3 476	-12 854	-4 422
Cash flow from investing activities	-1 233	-942	-1 095	-690	-866	-4 598	-1 573	-2 875
Cash flow from financing activities	38 640	8 646	-1 329	-1 329	2 249	-1 230	-1 397	-479
Total cash flow for actual period	25 399	-7 040	-17 637	-16 171	-12 269	-9 304	-15 824	-7 776
Other Key Figures								
Equity ratio, % *	19,5%	39,5%	52,5%	57,8%	60,4%	61,4%	63,5%	65,9%
Number of employees at the end of the period	17	18	17	20	20	20	19	20
Number of employees on average during the period	18	17	17	20	20	18	19	20
Average number of employees and consultants during the period	19	20	20	23	23	21	20	20
Data per share								
Earnings per share before and after dilution, SEK	-0,48	-0,57	-0,54	-0,45	-0,33	-0,28	-0,20	-0,21
Equity per share (before dilution), SEK *	0,79	1,27	1,83	2,37	2,82	3,06	3,35	3,56
Cash flow from operating activities per share, SEK	-0,43	-0,52	-0,54	-0,50	-0,49	-0,13	-0,46	-0,16
Share price at the end of the period, SEK	11,90	16,75	13,70	14,45	15,15	16,45	13,40	14,00
Number of shares before dilution on average during the period	28 165 826	28 165 826	28 165 826	28 165 826	27 918 262	27 788 212	27 723 273	27 699 077
Number of shares before dilution at the end of the period	28 165 826	28 165 826	28 165 826	28 165 826	28 165 826	27 794 480	27 776 850	27 699 077
Number of warrants at the end of the period	28 165 826	1 719 949	1 719 949	919 949	919 949	1 291 745	1 336 875	1 414 648
Number of shares after dilution at the end of the period	1 719 949	1 719 949	29 885 775	29 085 775	29 085 775	29 086 225	29 113 725	29 113 725

* Alternative key figures that are not defined by IFRS. For definition, please see note 9..

For further information, please contact:

CEO Andreas Bhagwani, ph. 070-316 17 02

CFO Eva Osterman, ph. 072-180 30 75

The information is information that Nanologica AB is obliged to make public pursuant to the EU Market Abuse Regulation). The information was submitted for publication, through the agency of the contact persons above, on August 19, 2022, at 08.00 (CET).



Nanologica AB (publ)

Forskargatan 20 G

151 36 Södertälje

Tel: 08-410 749 49

www.nanologica.com